All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
For patients with myelofibrosis (MF), transplant suitability is determined by several factors, including age, disease status, comorbidities, performance status, and donor availability, and is currently, based on the Myelofibrosis Transplant Scoring System (MTSS).1
Recently, a new scoring system, the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI), has been identified to assess role of comorbidities and body mass index (BMI) in transplant prognostication for patients with MF. Here, we summarize a retrospective study by Polverelli N et al.1
Table 1. 5-year survival rates in patients with low-, intermediate-, and high-risk patients with MF*
Category, % (unless stated otherwise) |
Low risk (0), |
Intermediate risk (1,2), |
High risk (≥3), |
---|---|---|---|
5-year NRM |
27 |
33 |
36 |
5-year OS |
58 |
52 |
46 |
OS, overall survival; NRM, non-relapse mortality. |
Key learnings |
---|
|
Your opinion matters
Subscribe to get the best content related to MPN delivered to your inbox